期刊文献+

二甲双胍对2型糖尿病胰岛素抵抗的影响 被引量:8

Effects of Metformin on Insulin Resistance in Type 2 Diabetes
下载PDF
导出
摘要 目的:探讨二甲双胍对2型糖尿病胰岛素抵抗的影响。方法:选取2015年1月至2015年5月我院收治的30例2型糖尿病胰岛素抵抗患者作为研究对象,将患者分为对照组和观察组,每组各15例,对照组采用安慰剂治疗,观察组采用二甲双胍治疗,观察二甲双胍对2型糖尿病胰岛素抵抗的治疗效果。结果:对照组患者治疗前后的空腹血糖、餐后2 h血糖、胰岛素使用剂量无明显变化。与治疗前相比,治疗后观察组患者的空腹血糖、餐后2 h血糖、胰岛素使用剂量明显减少(P<0.05)。结论:二甲双胍治疗2型糖尿病胰岛素抵抗具有良好效果。 Objective To investigate the effect of metformin on insulin resistance in type 2 diabetes.Methods 30 cases of type 2 diabetes patients with insulin resistance from January 2015 to May 2015 in our hospital were selected as research subjects in this study.All patients were treated with metformin,the effects of Metformin on insulin resistance in type 2 diabetes was observed.Results Compared with before treatment,fasting blood glucose,postprandial 2h blood glucose,insulin dose was significantly reduced after treatment(P〈0.05).Conclusion Treatment with metformin on insulin resistance in type 2 diabetes has a good effect,it is worthy to be used.
作者 赵茜
出处 《深圳中西医结合杂志》 2015年第17期9-10,共2页 Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词 二甲双胍 2型糖尿病 胰岛素抵抗 Metformin Type 2 diabetes Insulin resistance
  • 相关文献

参考文献5

二级参考文献24

  • 1Tankova T.Current indications for metformin therapy[J].Rom J Intern Med,2003,41 (3):215.
  • 2Sivertsen J, Rosenmeier J, Holst J J, et al. The effect of gluca- gon-like peptidel on cardio-vascular risk [ J ]. Nat Rev Cardiol, 2012, 9(4) :209 -22.
  • 3Mu J, Woods J, Zhou Y P, et al. Chronic inhibition of dipeptidy peptidase-4 with a sitagliptin analog preserves pancreatic 13-cellmass and function in a rodent model of type 2 diabetes[ J]. Diabe- tes ,2006,55 ( 6 ) : 1695 - 1704.
  • 4Flock C, Baggio L L, Longuet C, et al. Incretin receptors for glu- cagon-like peptide 1 and glucose-dependent insulin otropic poly- peptide are essential for the sustained metabolication of vildagliptin in mice[J]. J Diabetes, 2007, 56(4): 3006-13.
  • 5Monami M, Lacomellil, Marchionni N, et al. Dipeptydil peptidase - 4 inhibitors in type 2 diabetes: ameta-analysis of randomized clini- cal trials[J]. Nun" Metab Cardiovase Dis,2010,20(4) : 224 -35.
  • 6Jendle J, Nauck M A, Matthews D R, et al. Weight loss with lira- glutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue[J]. Diabetes Obes Metab ,2009,11 ( 12 ) : 1163 - 72.
  • 7Charbonnel B, Karasik A, Liu J , et al. Efficacy and safety of the dipeptidy peptidase-4 inhibitor sitagliptin added to ongoing met- formin therapy in patients with type 2 diabetes inadequately con- trolled with metformin alone[ J]. Diabetes Care,2006, 29 (12) : 2638 - 43.
  • 8Buse J B, Polonsky K S, Burant C F,et al. Type 2 diabetes melli- tus in 2010: individualizing treatment targets in diabetes care[ J]. Nat Rev Endocrinol, 2011,7(2) :67 -8.
  • 9Tremblay A J, Lamarche B, Lemelin N, et al. Effect of sitagliptin therapy on postprandial lipoprotein level in patient with type 2 dia- betes[J]. Diabetes Obes Metab,2011,13(4) : 366 -73.
  • 10Khurana R,Malik IS.Metformin:safety in cardiac patients〔J〕. Postgraduate Medical Journal . 2010

共引文献86

同被引文献78

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部